The online DNA network has delved into self-reported data of more than 563,000 US adults to help identify genetic risk of infection and severe outcomes.
As the pandemic continues to impact the globe, the agency has kept busy issuing EUAs for potential treatments, and cited sellers of unapproved treatments.
Taking place December 9, the Digital Advances in Clinical Trials webinar covers notable advances in clinical trial technology, and the future of the field.
Health tech specialists GoodCell are working with the New York Blood Center to identify COVID-19 patients with elevated risk of adverse clinical outcomes.
The global biopharma is using Reify Health’s StudyTeam software to streamline and automate clinical trial functions, including recruiting and enrollment.
A recent survey conducted by Oracle reveals trial professionals’ thoughts, feelings and behavior around decentralized research in the face of the pandemic.
The division of the National Institutes of Health has begun enrolling hospitalized patients in a trial investigating various potential COVID-19 treatments.
The company has received a $500,000 grant from the COVID-19 Therapeutics Accelerator to develop manufacturing processes for the antiviral drug remdesivir.
The clinical site services provider continues its series of strategic company purchases by bringing the Irish trial technologies firm under its umbrella.
Intelligent Tissue Group has launched its Intelligent Clinical trials facility to help assess the effectiveness and safety of potential new treatments.
The pharma giant and the clinical-stage drug developer will join on a pilot study investigating a candidate’s potential in overcoming resistance of a cancer drug.
The agency has given the go-ahead for use of baricitinib in conjunction with remdesivir for treating patients hospitalized with severe cases of the virus.
A leader from the global CRO shares an update on their new Accellacare clinical research network, and perspective on the importance of patient centricity.
RedHill Biopharma has completed enrollment for its Phase II study exploring the use of opaganib in treating COVID-19 patients that have severe pneumonia.
A leader from the CRO discusses how the COVID-19 pandemic has accelerated decentralized adoption, and how such trials lead to benefits for participants.
According to one New Yorker, encountering the AI-assisted TrialJectory technology helped cut through the uncertainty to provide information and solutions.
The precision medicine firm is joining with the oncology network in an effort to help improve treatment options and outcomes for cancer patients worldwide.
An expert from the global pharmaceutical firm shares how working with other organizations and putting patients at the center can benefit clinical research.
The federal agency has offered updates, advice and action regarding the COVID-19 pandemic, helping life-sciences professionals stay on top of developments.
During a free editorial webinar on December 9, a panel of clinical trial experts will offer a range of insights into the future of research technology.
A leader from the global CRO talks about how use of RWE in clinical trials can benefit research sites and sponsors, and satisfy regulatory requirements.
The company’s annual survey of pharmaceutical and biotechnology leaders reveals their needs, plans and concerns for the immediate and long-term future.
The clear evidence of increased risk of COVID-19 infection amongst ethnic minority groups, people from Black and Asian backgrounds, is of urgent public health importance, according to the authors of a paper published today by The Lancet.
Preliminary results from a recent clinical trial indicate the drug touted by US leaders as a possible treatment offers no significant benefit to patients.
With the Open Wearables initiative, Shimmer Research is looking to bring research professionals together on solutions for the common good of the industry.
The latest analytical report from Life Science Strategy Group reveals position and perception of the leading players and performers in the eClinical arena.
Mission Bio has launched a tool it claims will help save the industry billions of dollars in drug development costs and bring life-saving treatments to market at least six months faster.
In order to effectively handle collection and analysis of huge volumes of vital data, a leader from IQVIA advises bringing on people up to the challenge.
A leader from the cancer patient matching and analysis solutions firm discusses how and other forces are pushing innovation in the oncology research space.
